Skip to content
RDL Network logo
JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma — Satoshi Kobayashi (2017) | RDL Network